EyePoint Pharmaceuticals Newsroom

Capital One Financial Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Maintains Target Price $35

Futu NewsSep 16 21:32

EyePoint Pharmaceuticals Price Target Announced at $15.00/Share by Jefferies

Dow JonesAug 28 20:32

Jefferies Initiates EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Announces Target Price $15

Futu NewsAug 28 17:31

Outperform Rating Reaffirmed for EyePoint Pharmaceuticals Amidst Promising Duravyu Developments

TipRanksAug 16 18:06

EyePoint Pharmaceuticals Analyst Ratings

BenzingaAug 13 20:35

JP Morgan Maintains Overweight on EyePoint Pharmaceuticals, Lowers Price Target to $29

BenzingaAug 13 20:35

J.P. Morgan Maintains EyePoint Pharmaceuticals(EYPT.US) With Buy Rating, Cuts Target Price to $29

Futu NewsAug 13 20:33

Analysts Offer Insights on Healthcare Companies: EyePoint Pharmaceuticals (EYPT), Sarepta Therapeutics (SRPT) and Intra-Cellular Therapies (ITCI)

TipRanksAug 9 19:07

Optimistic 'Buy' Rating for EyePoint Pharmaceuticals Amidst Promising DURAVYU Trial Prospects

TipRanksAug 9 00:31

Buy Rating Justified by EyePoint Pharmaceuticals' Strong Financials and Promising DURAVYU Trials

TipRanksAug 8 04:21

EyePoint Pharmaceuticals Earns Buy Rating on Duravyu's Promising Efficacy and Safety Profile

TipRanksAug 7 21:58

Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Maintains $28 Price Target

BenzingaJun 28 20:32

EyePoint Pharmaceuticals Analyst Ratings

BenzingaJun 27 18:17

HC Wainwright & Co. Reiterates Buy on EyePoint Pharmaceuticals, Maintains $30 Price Target

BenzingaJun 27 18:17

EyePoint Pharmaceuticals Analyst Ratings

BenzingaJun 21 01:35

EyePoint Pharmaceuticals Analyst Ratings

BenzingaJun 4 21:20

JPMorgan Adjusts EyePoint Pharmaceuticals Price Target to $32 From $35, Maintains Overweight Rating

MT NewswiresJun 4 19:38

Buy Rating Affirmed for EyePoint Pharmaceuticals Amidst Promising Phase 3 Trials and FDA Alignment

TipRanksMay 31 10:27

HC Wainwright & Co. : The EyePoint Pharmaceuticals (EYPT.US) rating was maintained, adjusted from buy to buy rating, and the target price was adjusted from $33.00 to $30.00.

Zhitong FinanceMay 13 19:03

EyePoint Pharmaceuticals Analyst Ratings

BenzingaMay 13 19:00